JP2017516770A - 眼の治療用組成物 - Google Patents

眼の治療用組成物 Download PDF

Info

Publication number
JP2017516770A
JP2017516770A JP2016568504A JP2016568504A JP2017516770A JP 2017516770 A JP2017516770 A JP 2017516770A JP 2016568504 A JP2016568504 A JP 2016568504A JP 2016568504 A JP2016568504 A JP 2016568504A JP 2017516770 A JP2017516770 A JP 2017516770A
Authority
JP
Japan
Prior art keywords
composition
cellulose
composition according
ectoine
lipid layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516770A5 (enExample
Inventor
ビルシュタイン，アンドレアス
ガラ，ハンス−ヨアヒム
ドウィヴェディ，ムリデュラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitop AG
Original Assignee
Bitop AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53433159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017516770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bitop AG filed Critical Bitop AG
Publication of JP2017516770A publication Critical patent/JP2017516770A/ja
Publication of JP2017516770A5 publication Critical patent/JP2017516770A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016568504A 2014-05-22 2015-05-22 眼の治療用組成物 Pending JP2017516770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102014007423.4A DE102014007423A1 (de) 2014-05-22 2014-05-22 Zusammensetzung zur Behandlung des Auges
DE102014007423.4 2014-05-22
PCT/EP2015/061434 WO2015177353A1 (de) 2014-05-22 2015-05-22 Zusammensetzung zur behandlung des auges

Publications (2)

Publication Number Publication Date
JP2017516770A true JP2017516770A (ja) 2017-06-22
JP2017516770A5 JP2017516770A5 (enExample) 2017-08-03

Family

ID=53433159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568504A Pending JP2017516770A (ja) 2014-05-22 2015-05-22 眼の治療用組成物

Country Status (10)

Country Link
US (3) US20170173012A1 (enExample)
EP (2) EP3977998A1 (enExample)
JP (1) JP2017516770A (enExample)
CN (1) CN106456537A (enExample)
CA (1) CA2949203C (enExample)
DE (1) DE102014007423A1 (enExample)
ES (1) ES2906431T3 (enExample)
PL (1) PL3145511T3 (enExample)
RU (1) RU2016150412A (enExample)
WO (1) WO2015177353A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016203696A1 (de) * 2016-03-07 2017-09-07 Ursapharm Arzneimittel Gmbh Ophthalmologische Zusammensetzung
DE102016204472A1 (de) * 2016-03-17 2017-09-21 Ursapharm Arzneimittel Gmbh Kit zur kosmetischen Behandlung des Auges und der Haut und Kosmetikum zur Anwendung am Auge und auf der Haut
EP3827818A1 (en) * 2019-11-26 2021-06-02 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
CN111991415B (zh) * 2020-09-11 2022-03-01 华熙生物科技股份有限公司 一种眼部护理组合物及其制备方法和用途
US12012238B2 (en) 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
CN116139067B (zh) * 2021-11-22 2024-03-22 华熙生物科技股份有限公司 透明质酸锌形成凝胶的方法及含有透明质酸锌的滴眼凝胶及其制备

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336442A (ja) * 1993-04-02 1994-12-06 Wakamoto Pharmaceut Co Ltd 安定なリポソーム水分散液
WO1996019211A1 (en) * 1994-12-19 1996-06-27 Taisho Pharmaceutical Co., Ltd. Liposome eye drops
JPH092944A (ja) * 1994-07-26 1997-01-07 Motetsu Ko 眼用医薬組成物及びその投与方法
JPH0977656A (ja) * 1995-09-14 1997-03-25 Toshihiro Handa 点眼用エアゾル組成物
CN101491525A (zh) * 2009-03-03 2009-07-29 山东大学 四氢嘧啶在制备治疗干眼症药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716376D0 (en) * 1997-08-01 1997-10-08 Isis Innovation Artificial tear formulation
DE10006578C2 (de) 2000-02-14 2002-10-31 Bitop Ag Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
DE10330243A1 (de) 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
US20080132444A1 (en) * 2004-10-09 2008-06-05 Xiaoling Li Ocular Agent Delivery Systems
DE102006056766A1 (de) 2006-12-01 2008-06-05 Bitop Ag Verwendung von kompatiblen Soluten
CN101605531B (zh) * 2007-02-09 2012-10-10 爱尔康公司 含有三种聚合物的协同组合的眼用组合物
DE102007052380A1 (de) * 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
EP2823814A1 (en) * 2009-06-10 2015-01-14 Mitotech SA Pharmaceutical composition for use in medical and veterinary ophthalmology
US20110300097A1 (en) * 2010-06-04 2011-12-08 Al-Qahtani Ahmed H Method And Composition For The Treatment Of Moderate To Severe Keratoconjunctivitis Sicca
DE102011113059A1 (de) * 2011-09-09 2013-03-14 Bitop Ag Therapeutische Anwendungen von Ectoin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336442A (ja) * 1993-04-02 1994-12-06 Wakamoto Pharmaceut Co Ltd 安定なリポソーム水分散液
JPH092944A (ja) * 1994-07-26 1997-01-07 Motetsu Ko 眼用医薬組成物及びその投与方法
WO1996019211A1 (en) * 1994-12-19 1996-06-27 Taisho Pharmaceutical Co., Ltd. Liposome eye drops
JPH0977656A (ja) * 1995-09-14 1997-03-25 Toshihiro Handa 点眼用エアゾル組成物
CN101491525A (zh) * 2009-03-03 2009-07-29 山东大学 四氢嘧啶在制备治疗干眼症药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M DWIVEDI ET AL.: "Biophysical investigations of the structure and function of the tear fluid lipid layer and the effec", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1838, JPN6019001995, 17 May 2014 (2014-05-17), pages 2708 - 2715, ISSN: 0004143838 *
M DWIVEDI ET AL.: "Biophysical investigations of the structure and function of the tear fluid lipid layer and the effec", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1838, JPN6019001998, 20 May 2014 (2014-05-20), pages 2716 - 2727, ISSN: 0004143839 *

Also Published As

Publication number Publication date
WO2015177353A1 (de) 2015-11-26
EP3977998A1 (de) 2022-04-06
CA2949203A1 (en) 2015-11-26
EP3145511A1 (de) 2017-03-29
DE102014007423A1 (de) 2015-11-26
RU2016150412A3 (enExample) 2019-01-17
US20250195515A1 (en) 2025-06-19
CA2949203C (en) 2023-10-31
ES2906431T3 (es) 2022-04-18
PL3145511T3 (pl) 2022-05-02
RU2016150412A (ru) 2018-06-25
US20220133719A1 (en) 2022-05-05
US20170173012A1 (en) 2017-06-22
EP3145511B1 (de) 2022-01-05
CN106456537A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
US20250195515A1 (en) Composition for treating the eye
JP7224095B2 (ja) 眼科用組成物
AU2011282681B2 (en) Preservative free bimatoprost and timolol solutions
JP2012519664A (ja) プロスタグランジンを含有するアニオン性水中油型エマルジョンおよびその使用
JP2018503670A (ja) ポリアフロンおよびその眼瞼投与
WO2010075315A2 (en) Topical formulations of flap inhibitors for administration to an eye
WO2012015996A2 (en) Preservative free bimatoprost solutions
EP3407975B1 (en) Use of prostacyclin antagonists for treating ocular surface nociception
ES2984281T3 (es) Composiciones que comprenden un antagonista de la aldosterona para su uso en el tratamiento de ojos secos
KR101433396B1 (ko) 안구 적용용 아마인 추출물 약제
JP4263418B2 (ja) 熱ゲル化人工涙液
JP2016196454A (ja) 涙腺ドラッグデリバリーシステム
EP4302767B1 (en) Ophthalmic composition comprising eriocitrin for treating dry eye syndrome
JP2006089460A (ja) 眼科用粘稠化剤
WO2025040605A1 (de) Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-modulator zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge
EP3278804A1 (en) Dry eye therapeutic agent having as active ingredient nandrolone or ester thereof or methenolone or ester thereof
JPWO2001041806A1 (ja) 眼科用組成物
DE202014011522U1 (de) Zusammensetzung zur Behandlung des Auges

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191106